NXGLWNasdaqSurgical & Medical Instruments & ApparatusUS GAAP · USD

NexGel, Inc

NEXGEL, Inc. develops and manufactures aqueous polymer hydrogel products used in wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company operates through contract manufacturing, custom and white-label products, consumer branded products, and medical devices/other, serving customers in the United States and through online and retail channels.

Kysy yhtiöstä
Liikevaihto11,4milj. USD
+31,5 %v/v
Liikevoitto (EBIT)−3,4milj. USD
+5,7 %v/v
EBIT-marginaali−29,3%
+11,6 %-yks.v/v
Nettotulos−3,0milj. USD
+8,6 %v/v
Vapaa kassavirta−1,4milj. USD
+68,0 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−5051015milj. USD2020: 0,67 milj. USD2020: EBIT −2,3 milj. USD20202021: 1,6 milj. USD2021: EBIT −2,6 milj. USD20212022: 2,0 milj. USD2022: EBIT −3,3 milj. USD20222023: 4,1 milj. USD2023: EBIT −3,5 milj. USD20232024: 8,7 milj. USD2024: EBIT −3,6 milj. USD20242025: 11 milj. USD2025: EBIT −3,4 milj. USD202511−3,4
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: NexGel, Inc

Liiketoiminta

Osuus liikevaihdosta
Contract Manufacturing35 %

Rollstock gel manufactured for third parties that package it into finished goods.

Custom & White Label25 %

Customized gel products developed, converted, and packaged for branding partners.

Consumer Branded Products35 %

Finished goods sold directly to consumers under MedaGel, Kenkoderm, and Silly George.

Medical Devices/Other5 %

Development-stage medical devices and ancillary freight or other revenue items.

Asiakkaat

NEXGEL sells to industrial and brand-owner customers that need gel rollstock or finished private-label products, as well as end consumers buying branded products online and through retail channels. Its customer base also includes strategic partners for future medical device commercialization and distributors that can bring niche products to market.

Contract manufacturing customers

Buy gel rollstock and package it into their own finished products.

Custom and white-label brand partners

Buy tailored gel formulations and finished goods for their brands.

Direct-to-consumer shoppers

Buy MedaGel, Kenkoderm, and Silly George products through online and retail channels.

Medical device partners

Work with the company on future device and drug-delivery products.

Strategia

NEXGEL is building a multi-channel model that combines contract manufacturing, custom product development, and consumer brands. Management is also pursuing new product channels, additional branded acquisitions, and proprietary medical device and drug-delivery opportunities to broaden the revenue base and reduce reliance on any single line of business.

Expand consumer branded productsLyhyt aikaväli

Branded products can improve control over pricing, marketing, and distribution.

Maintain and grow contract manufacturingLyhyt aikaväli

Rollstock production remains a core industrial revenue stream and supports utilization.

Pursue acquisitions and new product channelsKeskipitkä aikaväli

Acquisitions and channel expansion can diversify the customer base and product mix.

Develop proprietary medical devicesKeskipitkä aikaväli

Higher-value device and drug-delivery products could extend the technology platform.

Maantiede

NEXGEL is a U.S.-based business with manufacturing and commercial activity centered in the United States. The company also operates through a joint venture in Granbury, Texas, and sells consumer products through online marketplaces and retail channels, which can broaden reach beyond its manufacturing footprint.

Riskit

NEXGEL faces execution risk from its dependence on a small set of product lines, customer development cycles, and the need to scale new brands and devices. As a development- and acquisition-oriented company, it also carries financing, going-concern, and valuation risk, while consumer and medical products expose it to regulatory, commercialization, and demand variability.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Going-concern and financing dependence1Commercialization risk on consumer brands3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Going-concern and financing dependenceVaikutus: KorkeaTodennäköisyys: Korkea

    The company may need additional debt or equity to fund growth and acquisitions.

    Kohdistuu: Corporate funding and expansion plans

  2. Customer concentration and order volatilityVaikutus: Korkea

    Contract manufacturing and custom products can be lumpy and customer-specific.

    Kohdistuu: Rollstock and white-label orders

  3. Commercialization risk on consumer brandsVaikutus: KeskitasoTodennäköisyys: Matala

    Branded products depend on marketing, channel execution, and repeat demand.

    KohdistuuMedaGelKenkodermSilly George
  4. Medical device development riskVaikutus: Keskitaso

    New devices may not reach market or may require partner support to scale.

    Kohdistuu: Proprietary medical devices and drug delivery

  5. Regulatory and product liability riskVaikutus: Keskitaso

    Healthcare, OTC, and cosmetic products face quality, labeling, and compliance requirements.

    KohdistuuWound careOTC remediesSkincareBeauty products
Kysy Clarifolta: NexGel, Inc

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition across multiple business lines

Different lines may recognize revenue at shipment, delivery, or fulfillment completion.

Vaikutus: Affects quarterly comparability and reported mix between contract and branded sales

Warrant liability fair value

Outstanding warrants are remeasured using valuation assumptions.

Vaikutus: Can create non-cash gains or losses in other income/expense

Share-based compensation

Option grants are valued with Black-Scholes and expensed over vesting.

Vaikutus: Affects operating expenses and earnings volatility

Long-lived asset and acquisition impairment

Growth investments and acquired brands require recoverability testing.

Vaikutus: Could lead to impairment charges if expected cash flows weaken

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Vericel Corp

VCEL · Biological Products, (No Diagnostic Substances)

Nexalin Technology, Inc.

NXL · Electromedical & Electrotherapeutic Apparatus

XCel Brands, Inc.

XELB · Patent Owners & Lessors

Regenerex Pharma, Inc.

Pharmaceutical Preparations

HEXPOL B

HPOL-B · Basic Materials

NextNRG, Inc

NXXT · Retail-Auto Dealers & Gasoline Stations

Päivitetty: 24.9.2026